Grace Therapeutics, Inc. (GRCE)
| Market Cap | 44.49M +4.2% |
| Revenue (ttm) | n/a |
| Net Income | -20.22M |
| EPS | -1.20 |
| Shares Out | 21.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,020 |
| Open | 2.140 |
| Previous Close | 2.130 |
| Day's Range | 2.100 - 2.170 |
| 52-Week Range | 1.790 - 5.180 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 6.02 (+184.63%) |
| Earnings Date | Aug 13, 2026 |
About GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The co... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for GRCE stock is "Strong Buy." The 12-month stock price target is $6.02, which is an increase of 184.63% from the latest price.
News
Grace Therapeutics Slides: Corporate presentation
Grace Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, no...
Grace Therapeutics files to sell 4.76M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 4.76M shares of common stock. The company is not selling any…
Grace Therapeutics Registration statement: Registration filing
Grace Therapeutics filed a registration statement on August 24, 2026, providing details about a securities offering with the SEC.
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov...
Grace Therapeutics Quarterly report: Q1 2027
Grace Therapeutics has published its Q1 2027 quarterly earnings report on August 13, 2026.
Grace Therapeutics Earnings release: Q1 2027
Grace Therapeutics released its Q1 2027 earnings on August 13, 2026, summarizing the period's financial results.
Grace Therapeutics to issue 4.762M shares at $2.10 in private placement
Grace Therapeutics (GRCE) announced that it has entered into a securities purchase agreement for a private placement financing with new and existing fundamental investors. The financing is expected to...
Grace Therapeutics initiates dual-source manufacturing strategy for GTx-104
In parallel, the company has initiated a dual-source manufacturing strategy for GTx-104 to mitigate potential remediation issues from the company’s current contract manufacturer and provide flexibilit...
Grace Therapeutics Announces $10 Million Private Placement
Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028
Grace Therapeutics Proxy statement: Proxy filing
Grace Therapeutics filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
Grace Therapeutics Proxy statement: Proxy filing
Grace Therapeutics filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
Grace Therapeutics receives Type A meeting minutes from FDA
Grace Therapeutics (GRCE) announced receipt of the FDA meeting minutes from a Type A meeting held with the FDA to discuss the complete response letter, or CRL, issued on April…
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward ...
Grace Therapeutics Slides: Corporate presentation
Grace Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
Grace Therapeutics reports FY26 EPS (47c) vs (79c) last year
“Since receipt of the U.S. Food and Drug Administration’s (FDA) Complete Response Letter in April 2026, we have been working diligently on addressing the cited items, and we look forward…
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pr...
Grace Therapeutics Annual report: Q4 2026
Grace Therapeutics has published its Q4 2026 annual report on June 18, 2026.
Grace Therapeutics Earnings release: Q4 2026
Grace Therapeutics released its Q4 2026 earnings on June 18, 2026, summarizing the period's financial results.
Grace Therapeutics Slides: Corporate presentation
Grace Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 18, 2026.
Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Grace Therapeutics (GRCE) to $4 from $11 and keeps a Buy rating on the shares following the CRL to GTx-104. FDA cited CMC…
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen
TD Cowen analyst Stacy Ku lowered the firm’s price target on Grace Therapeutics (GRCE) to $8 from $12 and keeps a Buy rating on the shares. The firm said GTx-104’s…
Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104
Shares of Grace Therapeutics (GRCE) are down $2.07, or 48%, to $2.24 after the FDA issued a Complete Response Letter for the company’s New Drug Application for GTx-104 for the…
Grace Therapeutics, Inc trading resumes
13:45 EDT Grace Therapeutics (GRCE), Inc trading resumes
US FDA declines to approve Grace Therapeutics' drug for a type of stroke
Grace Therapeutics said on Thursday the U.S. Food and Drug Administration declined to approve its drug for a rare type of stroke.